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1. Introduction 
5,6-seco-Germacrane lactone (1) was isolated from an extract 
of Santolina chamaecyparissus L. ssp. squarrosa (DC.) Nyman, 
naturally grown on the Mediterranean coast of Spain.1 The flower 
of this plant is used in folk medicine because of its antispasmodic, 
anti-inflammatory, antiseptic, antimicrobial, and digestive 
properties.2 In addition, this traditional general healing agent also 
has many positive effects, e.g., to improve headache, 
stomachache, dizziness, catarrh, and eye problems such as sties 
and eye fatigue, and its diuretic activity and blood cleansing 
abilities.3 The structural feature of 1 is an α-methylene lactonic 
acid having three stereogenic centers at the C1, C2, and C7 
positions. However, those absolute configurations remain a 
matter of speculation based on a plausible biogenetic pathway;1 
that is, 1 can be derived from the germacrane 2, which was 
isolated from the same extract, through oxidative cleavage of the 
C5–C6 bond to afford the intermediate seco-germacrane 
dicarboxylic acid, followed by a γ-lactonic ring-closing reaction 
(Scheme 1). This rational hypothesis is of interest because such a 
biosynthetic pathway of the linear sesquiterpene lactones has not 
been reported to our knowledge.4 For example, research on 
biosynthetic mechanisms for some analogues such as 
anthecotuloide5 and anthepseudolide6 from Anthemis sp. 
suggested that such irregular sesquiterpene lactones in nature 
could be formed from either the fragmentation of the 
corresponding germacranolides, which are derived from farnesyl 
diphosphate, or the condensation of geranyl diphosphate with 
dimethylallyl diphosphate followed by an oxidation process. 
Against this background, we initiated a synthetic study of 1 to 
establish those stereogenic centers and its biogenetic pathway, 
and to provide a sufficient amount of 1 synthetically for the 
evaluation of its biological activity. We describe herein the first 
total synthesis of (–)-1 from the known chiral building block (–)-
3. 
 
Scheme 1. Proposed Biogenetic Pathway of 1. 
2. Results and discussion 
We began the total synthesis of (–)-1 from the chiral building 
block (–)-3, which can be easily prepared from commercially 
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available 1,4-pentadien-3-ol in three steps, including the 
Sharpless asymmetric dihydroxylation.7,8a The allyl alcohol 
derivative (–)-3 was successfully converted into vinyl bromide (–
)-4 via the dibromo intermediate in excellent yield in a single pot 
(Scheme 2).8,9 The chiral HPLC analysis of (–)-4 revealed the 
enantiomeric purity of (–)-4 to be 95% ee.10 This two-step 
reaction was based on one-pot methodology for bromination of 
allyl alcohol derivatives and the sequential regioselective HBr 
elimination that was developed recently by our group.9  
 
Scheme 2. Synthesis of (‒)-4. 
Next, we synthesized the intermediate (–)-6 as the Suzuki–
Miyaura coupling partner with the vinyl bromide (–)-4 utilizing 
the method of zirconocene-catalyzed carbomagnesation described 
by Hoveyda et al.11 The reaction of 2,5-dihydrofuran with 5.1 
equiv of nPrMgCl in the presence of 10 mol % of (S)-
[EBTHI]ZrCl2 in THF at 70 °C produced homoallylic alcohol (–
)-5 and the subsequent TBDPS protection afforded (–)-6 in 32% 
yield in two steps (Scheme 3).  
 
Scheme 3. Synthesis of (‒)-6. 
 
Scheme 3. Total Synthesis of (‒)-1. 
We next attempted a B-alkyl Suzuki–Miyaura cross coupling 
with (–)-6 and (–)-4. Through trial and error,12 we found the 
optimal reaction conditions and procedure, as follows. 
Hydroboration of the terminal olefin (–)-6 with 9-
borabicyclo[3.3.1]nonane (9-BBN) dimer in THF was completed. 
After that, 3 M aqueous Cs2CO3 was added with vigorous stirring 
at room temperature for 50 min. Then, this solution was added to 
a solution of the vinyl bromide (–)-4 and catalytic amounts of 
Pd2(dba)3 and XPhos in 1,4-dioxane, and the mixture was stirred 
at 70 °C for 3.5 h to give the desired product (–)-7 in excellent 
yield (Scheme 4).13 Fortunately, no diastereomer was detected at 
the NMR analysis. This indicated that the coupling partner (‒)-6 
as well as (‒)-4 was almost optically pure. Introduction of an exo-
methylene group on the γ-lactone by the two-step Eschenmoser 
methylenation procedure,14 followed by removal of the TBDPS 
group using tetrabutylammonium fluoride, then provided (–)-9. 
Swern oxidation and the subsequent Pinnick oxidation gave the 
corresponding γ-lactonic acid (–)-11 in sufficient yield, without 
any epimerization in the process. At the final stage, the p-
methoxybenzyl group of (–)-11 was removed with DDQ to afford 
(–)-1 in moderate yield, which was identical spectroscopically to 
that reported by Carda et al.1 
3. Conclusion 
In conclusion, the first total synthesis of (–)-1 was achieved 
from the known chiral building block (–)-3 with diversity in eight 
steps and an overall yield of 14%. The key step in our synthesis 
was an sp2–sp3 Suzuki–Miyaura cross coupling between the vinyl 
bromide (–)-4 and the alkylborane derived from (–)-6. Our 
synthetic strategy would allow the synthesis of the related 
analogues and derivatives of 1, including its diastereomers, 
without any difficulty. In addition, through this synthetic research, 
the absolute stereochemistries of all stereogenic carbon centers in 
1 were determined, and thereby its novel biosynthetic mechanism, 
as proposed by Carda et al., could be strongly supported. A 
further investigation related to the synthesis of analogues and 
their biological assay is in progress. 
4. Experimental section 
4.1. General remarks 
Infrared spectra were recorded with a Horiba FT-710 model 
spectrophotometer. 1H and 13C NMR spectral data were obtained 
with a Bruker Avance 600, a JEOL JNM-LA 500 instruments. 
Chemical shifts are quoted in ppm using tetramethylsilane (TMS, 
δ = 0 ppm) as the reference for 1H NMR spectroscopy, and 
CDCl3 (δ = 77.0 ppm) for 13C NMR spectroscopy. Mass spectra 
were measured with a Bruker Daltonics microTOF or a Hitachi 
double-focusing M-80B spectrometer. Column chromatography 
was carried out on silica gel (Kanto Chemical Co. or Merck Co. 
Ltd). All reactions were performed under an argon atmosphere. 
Compounds 3, 4, and 5 are known and their analytical data have 
been reported.15  
4.2. One-pot synthesis of (R)-5-[(S)-2-bromo-1-(4-
methoxybenzyloxy)allyl]dihydrofuran-2(3H)-one ((‒)-4) 
A mixture of the lactone (‒)-3 (0.45 g, 1.7 mmol) and 
pyridinium bromide perbromide (>85%) (0.72 g, 1.9 mmol) in 
CH3CN (17 mL) was stirred at room temperature for 12 h. DBU 
(0.79 mL, 5.3 mmol) was added to the reaction mixture at 0 ºC 
and the mixture was then heated at 60 ºC for 5 h. The reaction 
was quenched with saturated aqueous NH4Cl at 0 ºC, and the 
reaction mixture was extracted with ethyl acetate (20 mL x 3), 
washed with brine (20 mL), dried over MgSO4, concentrated in 
vacuo, and purified by silica gel column chromatography 
(CHCl3/CH3CN = 20/1) to afford the bromoalkene (‒)-4 (0.55 g, 
94%). 
4.3. (R)-3-[(tert-buthyldiphenylsilyloxy)methyl]-4-methylpent-1-
ene ((‒)-6) 
2,5-Dihydrofuran (0.10 mL, 1.4 mmol) was dissolved in 
anhydrous THF (1.6 mL) in a flamed-dried 30 mL round-bottom 
flask. After the addition of nPrMgCl (2.0 M in Et2O, 3.4 mL, 6.8 
 3 
mmol), the reaction mixture was allowed to stir for 5 min. Then, 
(S)-[EBTHI]ZrCl2 (59 mg, 0.14 mmol) was added and stirred at 
70 ºC for 6 h. After the solution was cooled to 0 ºC, excess 
Grignard reagent was quenched through the dropwise addition of 
1 M HCl aq. (9.0 mL). The mixture was diluted with H2O (30 
mL) and washed with methyl tert-butyl ether (10 mL × 3). 
Combined organic layers were dried over MgSO4, concentrated 
in vacuo, and the residue was diluted with CH2Cl2 (0.40 mL). 
After the addition of triethylamine (0.19 mL, 1.4 mmol), N,N-
dimethyl-4-aminopyridine (5.7 mg, 0.047 mmol), and TBDPSCl 
(0.14 mL, 0.54 mmol) at 0 ºC, the mixture was stirred at room 
temperature for 12 h. The reaction was quenched with H2O (10 
mL), and the reaction mixture was extracted with CHCl3 (10 mL 
× 3), dried over Na2SO4, concentrated in vacuo, and purified by 
silica gel column chromatography (hexane/ethyl acetate = 50/1) 
to afford (‒)-6 (0.15 g, 32% in 2 steps from 2,5-dihydrofuran) as 
a pale yellow oil; [α]D20 ‒19.8º (c 1.00, CHCl3); IR (neat) 3070, 
2954, 2862, 2792, 1589, 1466, 1427, 1103, 995 cm-1; 1H NMR 
(500 MHz, CDCl3) δ = 0.80 (d, J = 6.6 Hz, 3H), 0.86 (d, J = 6.6 
Hz, 3H), 1.04 (s, 9H), 1.88 (dsep, J = 6.6, 6.6 Hz, 1H), 1.98‒2.06 
(m, 1H), 3.63 (dd, J = 10.0, 6.2 Hz, 1H), 3.67 (dd, J = 10.0, 6.2 
Hz, 1H), 4.97‒5.07 (m, 2H), 5.68 (ddd, J = 17.0, 10.0, 9.5 Hz, 
1H), 7.33‒7.44 (m, 6H), 7.66 (d, J = 6.3 Hz, 4H); 13C NMR (126 
MHz, CDCl3) δ = 18.7 (CH3), 19.3 (C), 20.9 (CH3), 26.9 (CH3 × 
3), 27.6 (CH), 52.8 (CH), 65.4 (CH2), 116.4 (CH2), 127.6 (CH × 
4), 129.5 (CH × 2), 134.0 (C × 2), 135.7 (CH × 4), 138.3 (CH); 
HRMS-ESI: m/z [M+Na]+ calcd for C23H32OSiNa: 375.2115, 
found: 375.2113. 
4.4. (R)-5-{(1R,5S)-5-[(tert-buthyldiphenylsilyloxy)methyl]-1-(4-
methoxybenzyloxy)-6-methyl-2-methyleneheptyl}dihydrofuran-
2(3H)-one ((‒)-7) 
A mixture of (‒)-6 (0.10 g, 0.29 mmol) and 9-BBN dimer (72 
mg, 0.30 mmol) in THF (0.65 mL) was stirred at room 
temperature for 1 h and then at 50 ºC for 3 h. After that, 3 M 
Cs2CO3 aq. (0.23 mL) was added with vigorous stirring at room 
temperature for 50 min. Then, this solution was added to a 
solution of the vinyl bromide (‒)-4 (46 mg, 0.13 mmol), 
Pd2(dba)3 (12.4 mg, 0.014 mmol), and XPhos (15.6 mg, 0.033 
mmol) in 1,4-dioxane (0.65 mL), and the mixture was stirred at 
70 ºC for 3.5 h. After the addition of H2O (10 mL), the reaction 
mixture was extracted with ethyl acetate (10 mL × 3), washed 
with brine (10 mL), dried over Na2SO4, concentrated in vacuo, 
and purified by silica gel column chromatography (hexane/ethyl 
acetate = 5/1) to afford (‒)-7 (73 mg, 89%) as a colorless oil; 
[α]D20 ‒30.8º (c 1.00, CHCl3); IR (neat) 3070, 2954, 2862, 1782, 
1612, 1466, 1250, 1111, 1033 cm-1; 1H NMR (500 MHz, CDCl3) 
δ = 0.85 (d, J = 7.1 Hz, 3H), 0.86 (d, J = 6.1 Hz, 3H), 1.05 (s, 
9H), 1.32‒1.40 (m, 1H), 1.45‒1.56 (m, 2H), 1.79‒1.95 (m, 3H), 
1.96‒2.09 (m, 2H), 2.31‒2.41 (m, 1H), 2.45‒2.55 (m, 1H), 3.55‒ 
3.66 (m, 2H), 3.70 (d, J = 5.8 Hz, 1H), 3.79 (s, 3H), 4.23 (d, J = 
11.4 Hz, 1H), 4.49 (ddd, J = 7.4, 6.7, 5.8 Hz, 1H), 4.52 (d, J = 
11.4 Hz, 1H), 5.11 (s, 2H), 6.85 (d, J = 8.3 Hz, 2H), 7.22 (d, J = 
8.3 Hz, 2H), 7.33‒7.44 (m, 6H), 7.65 (d, J = 7.2 Hz, 4H); 13C 
NMR (126 MHz, CDCl3) δ = 19.3 (C), 19.5 (CH3), 19.9 (CH3), 
24.5 (CH2), 26.2 (CH2), 26.9 (CH3 × 3), 28.3 (CH), 28.4 (CH2), 
29.5 (CH2), 46.4 (CH), 55.2 (CH3), 64.4 (CH2), 70.1 (CH2), 80.8 
(CH), 84.2 (CH), 113.8 (CH × 2), 114.7 (CH2), 127.6 (CH × 4), 
129.4 (CH × 2), 129.6 (CH × 2), 129.9 (C), 133.9 (C × 2), 135.6 
(CH × 4), 144.9 (C), 159.2 (C), 177.1 (C); HRMS-ESI: m/z 
[M+Na]+ calcd for C38H50O5SiNa: 637.3320, found: 637.3319. 
4.5. (R)-5-{(1R,5S)-5-[(tert-buthyldiphenylsilyloxy)methyl]-1-(4-
methoxybenzyloxy)-6-methyl-2-methyleneheptyl}-3-
methylenedihydrofuran-2(3H)-one ((‒)-8) 
To a mixture of (‒)-7 (0.10 g, 0.17 mmol), Eschenmoser’s 
salt (0.16 g, 0.85 mmol), and N,N-diisopropylethylamine (0.15 
mL, 0.85 mmol) in CH2Cl2 (1.7 mL) was added TMSOTf (33 μL, 
0.19 mmol) at 0 ºC. After being stirred at room temperature for 6 
min, the reaction was quenched with the addition of sat. NaHCO3 
aq. (5 mL), extracted with CHCl3 (10 mL × 3), washed with brine 
(10 mL), dried over MgSO4, and concentrated in vacuo. The 
resulting crude mixture was dissolved in CH2C2 (1.7 mL), and 
then, to the solution was added mCPBA (0.11 mg, 0.68 mmol) at 
0 ºC. After being stirred at room temperature for 1 h, the reaction 
was quenched with the addition of sat. Na2S2O3 aq. (10 mL), 
extracted with CHCl3 (10 mL × 3), washed with sat. NaHCO3 aq. 
(20 mL) and brine (10 mL), dried over MgSO4, concentrated in 
vacuo, and purified by silica gel column chromatography 
(CHCl3/CH3CN = 80/1) to afford (‒)-8 (66 mg, 61%) as a pale 
yellow oil; [α]D20 ‒30.6º (c 0.64, CHCl3); IR (neat) 3070, 2954, 
2862, 1766, 1612, 1466, 1250, 1111, 1034 cm-1; 1H NMR (500 
MHz, CDCl3) δ = 0.85 (d, J = 6.9 Hz, 3H), 0.86 (d, J = 6.5 Hz, 
3H), 1.05 (s, 9H), 1.33‒1.41 (m, 1H), 1.46‒1.56 (m, 2H), 
1.81‒1.94 (m, 2H), 1.97‒2.08 (m, 1H), 2.57 (dddd, J = 17.1, 6.0, 
3.0, 2.5 Hz, 1H), 2.72 (dddd, J = 17.1, 7.6, 2.9, 2.5 Hz, 1H), 
3.56‒ 3.66 (m, 2H), 3.69 (d, J = 6.0 Hz, 1H), 3.79 (s, 3H), 4.24 (d, 
J = 11.2 Hz, 1H), 4.44‒4.55 (m, 1H), 4.51 (d, J = 11.2 Hz, 1H), 
5.10 (br s, 1H), 5.12 (br s, 1H), 5.53 (dd, J = 2.5, 2.5 Hz, 1H), 
6.18 (dd, J = 3.0, 2.9 Hz, 1H), 6.85 (d, J = 8.5 Hz, 2H), 7.22 (d, J 
= 8.5 Hz, 2H), 7.33‒7.45 (m, 6H), 7.65 (d, J = 7.4 Hz, 4H); 13C 
NMR (126 MHz, CDCl3) δ = 19.3 (C), 19.6 (CH3), 19.9 (CH3), 
26.2 (CH2), 26.9 (CH3 × 3), 28.3 (CH), 29.4 (CH2), 30.0 (CH2), 
46.4 (CH), 55.3 (CH3), 64.4 (CH2), 70.2 (CH2), 77.4 (CH), 83.9 
(CH), 113.8 (CH × 2), 115.1 (CH2), 121.3 (CH2), 127.6 (CH × 4), 
127.7 (C), 129.4 (CH × 2), 129.6 (CH × 2), 129.9 (C), 133.9 (C), 
134.4 (C), 135.6 (CH × 4), 144.9 (C), 159.2 (C), 170.1 (C); 
HRMS-ESI: m/z [M+Na]+ calcd for C39H50O5SiNa: 649.3320, 
found: 649.3318. 
4.6. (R)-5-[(1R,5S)-5-hydroxymethyl-1-(4-methoxybenzyloxy)-6-
methyl-2-methyleneheptyl]-3-methylenedihydrofuran-2(3H)-one 
((‒)-9) 
A mixture of (‒)-8 (19 mg, 0.031 mmol) and TBAF (1 M in 
THF, 46 μL, 0.046 mmol) in THF (0.30 mL) was stirred at room 
temperature for 6 h. After the addition of sat. NH4Cl aq. (5.0 mL), 
the mixture was extracted with ethyl acetate (10 mL × 3), washed 
with brine (10 mL), dried over MgSO4, concentrated in vacuo, 
and purified by silica gel column chromatography (hexane/ethyl 
acetate = 5/1 to 1/1) to afford (‒)-9 (8.5 mg, 72%) as a pale 
yellow oil; [α]D20 ‒49.6º (c 1.00, CHCl3); IR (neat) 3502, 2954, 
2870, 1766, 1612, 1466, 1033 cm-1; 1H NMR (500 MHz, CDCl3) 
δ = 0.92 (d, J = 6.6 Hz, 6H), 1.29‒1.37 (m, 1H), 1.43‒1.64 (m, 
3H), 1.81 (m, 1H), 1.95‒2.17 (m, 2H), 2.68 (dddd, J = 17.5, 5.9, 
2.7, 2.4 Hz, 1H), 2.85 (dddd, J = 17.5, 8.5, 2.9, 2.4 Hz, 1H), 3.59 
(dd, J = 10.6, 5.8 Hz, 1H), 3.66 (dd, J = 10.6, 5.8 Hz, 1H), 3.76 
(d, J = 5.2 Hz, 1H), 3.80 (s, 3H), 4.27 (d, J = 12.0 Hz, 1H), 4.55 
(d, J = 12.0 Hz, 1H), 4.61 (ddd, J = 8.5, 5.9, 5.2 Hz, 1H), 5.14 (s, 
1H), 5.18 (s, 1H), 5.58 (dd, J = 2.4, 2.4 Hz, 1H), 6.20 (dd, J = 2.9, 
2.7 Hz, 1H), 6.87 (d, J = 8.3 Hz, 2H), 7.23 (d, J = 8.3 Hz, 2H); 
13C NMR (126 MHz, CDCl3) δ = 19.6 (CH3), 19.8 (CH3), 26.3 
(CH2), 28.2 (CH), 29.3 (CH2), 30.0 (CH2), 46.4 (CH), 55.3 (CH3), 
63.4 (CH2), 70.2 (CH2), 77.8 (CH), 83.5 (CH), 113.8 (CH × 2), 
115.4 (CH2), 121.4 (CH2), 129.4 (CH × 2), 129.8 (C), 134.3 (C), 
145.1 (C), 159.3 (C), 170.2 (C); HRMS-ESI: m/z [M+Na]+ calcd 
for C23H32O5Na: 411.2143, found: 411.2139. 
4.7. (S)-5-{(R)-(4-methoxybenzyloxy)[(R)-4-methylene-5-
oxotetrahydrofuran-2-yl]methyl}-2-isopropylhex-5-enal((‒)-10) 
To a solution of (COCl)2 (3.3 μL, 0.039 mmol) in CH2Cl2 (0.2 
mL) was added DMSO (2.7 μL, 0.038 mmol) at ‒78 ºC. The 
Tetrahedron 4 
mixture was stirred for 5 min, and (‒)-9 (7.5 mg, 0.019 mmol) 
in CH2Cl2 (0.6 mL) was added slowly. After being stirred at ‒78 
ºC for 1 h, triethylamine (16 μL, 0.12 mmol) was added and 
stirred for 2 h. After the addition of H2O (10 mL) at 0 ºC, the 
mixture was extracted with CHCl3 (5 mL × 3), washed with sat. 
NaHCO3 aq. (10 mL), sat. NH4Cl aq. (10 mL), and brine (10 mL), 
dried over MgSO4, concentrated in vacuo, and purified by silica 
gel column chromatography (hexane/ethyl acetate = 2/1) to 
afford (‒)-10 (7.2 mg, 97%) as a pale yellow oil; [α]D20 ‒28.8º (c 
1.00, CHCl3); IR (neat) 2954, 2931, 2870, 1766, 1720, 1612, 
1458, 1034 cm-1; 1H NMR (500 MHz, CDCl3) δ = 0.98 (d, J = 7.0 
Hz, 3H), 1.00 (d, J = 6.3 Hz, 3H), 1.55‒1.69 (m, 2H), 1.81‒1.90 
(m, 1H), 1.95‒2.09 (m, 2H), 2.13‒2.19 (m, 1H), 2.65 (dddd, J = 
17.1, 5.9, 3.1, 2.4 Hz, 1H), 2.85 (dddd, J = 17.1, 7.6, 2.7, 2.4 Hz, 
1H), 3.74 (d, J = 5.4 Hz, 1H), 3.80 (s, 3H), 4.27 (d, J = 11.3 Hz, 
1H), 4.54 (d, J = 11.3 Hz, 1H), 4.57 (ddd, J = 7.6, 5.9, 5.2 Hz, 
1H), 5.17 (s, 1H), 5.17 (s, 1H), 5.58 (dd, J = 2.4, 2.4 Hz, 1H), 
6.20 (dd, J = 3.1, 2.7 Hz, 1H), 6.87 (d, J = 8.4 Hz, 2H), 7.23 (d, J 
= 8.4 Hz, 2H), 9.66 (d, J = 3.4 Hz, 1H); 13C NMR (126 MHz, 
CDCl3) δ = 19.6 (CH3), 20.2 (CH3), 23.7 (CH2), 28.4 (CH), 29.3 
(CH2), 30.0 (CH2), 55.2 (CH3), 57.8 (CH), 70.3 (CH2), 77.4 (CH), 
83.5 (CH), 113.8 (CH × 2), 115.5 (CH2), 121.4 (CH2), 129.4 (CH 
× 2), 129.7 (C), 134.2 (C), 144.2 (C), 159.3 (C), 170.0 (C), 205.3 
(CH); HRMS-ESI: m/z [M+Na]+ calcd for C23H30O5Na: 409.1985, 
found: 409.1988. 
4.8. (S)-5-{(R)-(4-methoxybenzyloxy)[(R)-4-methylene-5-
oxotetrahydrofuran-2-yl]methyl}-2-isopropylhex-5-enoic acid 
((‒)-11) 
To a mixture of (‒)-10 (7.2 mg, 0.019 mmol) in tBuOH/H2O 
(0.30 mL/0.074 mL) was added 2-methyl-2-butene (10 μL, 0.094 
mmol) and NaH2PO4 (3.2 mg, 0.021 mmol) at room temperature, 
then NaClO2 (7.4 mg, 0.066 mmol) at 0 ºC. After being stirred at 
room temperature for 50 min, H2O (2.0 mL) and sat. NH4Cl aq. 
(10 mL) were added at 0 ºC. The mixture was extracted with 
ethyl acetate (10 mL × 3), dried over MgSO4, concentrated in 
vacuo, and purified by silica gel column chromatography (ethyl 
acetate) to afford (‒)-11 (6.6 mg, 88%) as a pale yellow oil; 
[α]D20 ‒49.3º (c 0.48, CHCl3); IR (neat) 3525, 2962, 2931, 2862, 
1766, 1705, 1612, 1466, 1033 cm-1; 1H NMR (500 MHz, CDCl3) 
δ = 0.98 (d, J = 6.9 Hz, 6H), 1.61‒1.86 (m, 2H), 1.87‒1.98 (m, 
1H), 1.98‒2.14 (m, 2H), 2.19‒2.26 (m, 1H), 2.64 (dddd, J = 17.1, 
5.2, 2.5, 2.4 Hz, 1H), 2.85 (dddd, J = 17.1, 7.6, 3.1, 2.7 Hz, 1H), 
3.74 (d, J = 5.8 Hz, 1H), 3.80 (s, 3H), 4.27 (d, J = 11.6 Hz, 1H), 
4.54 (d, J = 11.6 Hz, 1H), 4.58 (ddd, J = 7.6, 5.8, 5.2 Hz, 1H), 
5.16 (s, 2H), 5.57 (dd, J = 2.5, 2.4 Hz, 1H), 6.19 (dd, J = 3.1, 2.7 
Hz, 1H), 6.86 (d, J = 8.4 Hz, 2H), 7.22 (d, J = 8.4 Hz, 2H); 13C 
NMR (126 MHz, CDCl3) δ = 20.0 (CH3), 20.3 (CH3), 27.2 (CH), 
29.4 (CH2), 30.0 (CH2), 30.5 (CH2), 51.8 (CH), 55.3 (CH3), 70.3 
(CH2), 77.5 (CH), 83.5 (CH), 113.8 (CH × 2), 115.7 (CH2), 121.5 
(CH2), 129.4 (CH × 2), 129.7 (C), 134.3 (C), 144.0 (C), 159.3 (C), 
170.1 (C), 179.9 (C); HRMS-ESI: m/z [M+Na]+ calcd for 
C23H30O6Na: 425.1935, found: 425.1938. 
4.9. (‒)-5,6-seco-Germacrane Lactone ((‒)-1) 
A mixture of (‒)-11 (11 mg, 0.027 mmol) and DDQ (6.8 mg, 
0.030 mmol) in CH2Cl2/pH 6.9 phosphate buffer (0.45 mL/0.11 
mL) was stirred at room temperature for 12 h. After the addition 
of sat. NH4Cl aq. (5.0 mL) at 0 ºC, the mixture was extracted 
with ethyl acetate (10 mL × 3), dried over MgSO4, concentrated 
in vacuo, and purified by silica gel column chromatography 
(hexane/ethyl acetate = 1/3) to afford (‒)-1 (3.4 mg, 44%) as a 
colorless oil; [α]D20 ‒24.5º (c 0.17, CHCl3); IR (neat) 3452, 2962, 
2931, 2858, 1759, 1712, 1034 cm-1; 1H NMR (600 MHz, CDCl3) 
δ = 0.98 (d, J = 6.8 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H), 1.68‒1.86 
(m, 2H), 1.90‒1.97 (m, 1H), 2.03‒2.11 (m, 1H), 2.14‒2.25 (m, 
2H), 2.81 (dddd, J = 17.3, 5.6, 2.9, 2.4 Hz, 1H), 2.95 (dddd, J = 
17.3, 8.0, 2.7, 2.4 Hz, 1H), 4.07 (d, J = 5.7 Hz, 1H), 4.61 (ddd, J 
= 8.0, 5.7, 5.6 Hz, 1H), 5.08 (br s, 1H), 5.17 (br s, 1H), 5.66 (dd, 
J = 2.4, 2.4 Hz, 1H), 6.25 (dd, J = 2.9, 2.7 Hz, 1H); 13C NMR 
(150 MHz, CDCl3) δ = 20.0 (CH3), 20.4 (CH3), 27.5 (CH2), 29.8 
(CH), 29.9 (CH2), 30.6 (CH2), 51.6 (CH), 77.3 (CH), 78.1 (CH), 
114.2 (CH2), 122.6 (CH2), 133.9 (C), 146.0 (C), 170.0 (C), 179.3 
(C); HRMS-ESI: m/z [M+Na]+ calcd for C15H22O5Na: 305.1359, 
found: 305.1354. 
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